Qube Research & Technologies LTD An2 Therapeutics, Inc. Call Options Transaction History
Qube Research & Technologies LTD
- $72.9 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ANTX
# of Institutions
40Shares Held
17.6MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN5.75MShares$6.15 Million4.93% of portfolio
-
Almitas Capital LLC Santa Monica, CA1.31MShares$1.41 Million0.87% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.11 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny580KShares$620,3570.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY579KShares$619,3420.79% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $20.8M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...